Dimensional Fund Advisors LP lifted its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 599,812 shares of the company’s stock after acquiring an additional 9,672 shares during the period. Dimensional Fund Advisors LP owned 0.62% of Poseida Therapeutics worth $1,749,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blair William & Co. IL boosted its stake in Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares during the last quarter. Vanguard Group Inc. boosted its stake in Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Poseida Therapeutics by 177.3% during the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after buying an additional 40,245 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Poseida Therapeutics by 280.3% during the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after buying an additional 21,138 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new position in Poseida Therapeutics during the first quarter valued at approximately $33,000. 46.87% of the stock is owned by institutional investors.
Poseida Therapeutics Trading Up 1.6 %
Shares of PSTX stock opened at $2.51 on Friday. Poseida Therapeutics, Inc. has a 1 year low of $1.83 and a 1 year high of $4.27. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The stock’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $2.90. The company has a market cap of $243.80 million, a PE ratio of -2.11 and a beta of 0.51.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.
View Our Latest Research Report on Poseida Therapeutics
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Featured Articles
- Five stocks we like better than Poseida Therapeutics
- 3 Monster Growth Stocks to Buy Now
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Use Stock Screeners to Find Stocks
- 4 Quirky ETFs With Big Potential for Impressive Gains
Want to see what other hedge funds are holding PSTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report).
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.